ACT Mobile cGMP Connecticut

Press Release from Germfree Laboratories Inc

 

Breaking barriers in Malaria prevention with a mobile cGMP cleanroom facility

Germfree faced the challenge of designing and building a mobile cGMP cleanroom facility in which to conduct clinical trials for a novel Malaria vaccine.
 
 
Project features
 

Size: 420 sq ft / 39 sq metres gross area

Layout configurations: Two (2) ISO 7 cleanrooms and ISO 5 workstations, including gowning areas and an office, located on a semi-trailer chassis

Facilities/Equipment: Class 2, Type A2 Biosafety Cabinets

 

The challenge

Given the high risk nature of the research, Germfree needed to ensure strict adherence to aseptic techniques in the facility so that Artificial Cell Technologies could conduct cutting-edge research.

 

The answer

Germfree, a leading provider of advanced cleanroom solutions, successfully delivered a cutting-edge mobile cGMP cleanroom facility to Artificial Cell Technologies (ACT) in New Haven, Connecticut. The facility, which measures 420 sq. ft., features two ISO-7 cleanrooms, ISO-5 workstations, and gowning areas, as well as an office. Germfree’s experts were involved in every step of the process, ensuring that ACT received a top-quality facility to conduct clinical trials for the malaria vaccine.

The mobile cGMP cleanroom facility is built on a semi-trailer chassis and includes Class II, Type A2 biological safety cabinets in both cleanrooms, providing optimal protection against biohazards. With the support of the National Institute of Allergy and Infectious Diseases (NIAID), the facility was delivered to ACT in July 2016.

Germfree’s advanced solutions and expertise enable the safe and efficient production of life-saving vaccines, overcoming barriers in mobile cGMP cleanroom facilities. The successful delivery of the mobile cGMP cleanroom facility to ACT showcases Germfree’s commitment to providing innovative solutions that meet the unique needs of their clients and contribute to advancing healthcare globally

 
Companies Mentioned in this Press Release: